GlassScriptPhysician profile
Matthew D Kay
NPI 1568462489
$253,565.03
in general payments reported to CMS, 2019-2025
26 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,491 · 2020: $20K · 2021: $51K · 2022: $72K · 2023: $33K · 2024: $30K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Honoraria: $27K · Travel and Lodging: $12K · Food and Beverage: $7,102 · Consulting Fee: $3,825 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,637.50 |
| Honoraria | $26,962.50 |
| Travel and Lodging | $12,409.40 |
| Food and Beverage | $7,101.78 |
| Consulting Fee | $3,825.00 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $177,783.49 | 2019-2023 | Tepezza |
| Amgen INC. | $67,279.43 | 2024-2025 | Tepezza, Uplizna |
| Alexion Pharmaceuticals, INC. | $2,918.44 | 2019-2025 | Ultomiris |
| New World Medical,INC. | $967.73 | 2022 | |
| Abbvie INC. | $689.43 | 2023-2025 | |
| Alcon Vision LLC | $547.63 | 2019-2025 | Clareon, Hydrus Microstent, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $373.03 | 2021-2023 | Amo Phaco Needle |
| Allergan, INC. | $350.73 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $321.22 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $271.87 | 2021-2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.67 | 2019 | |
| Omeros Corporation | $249.99 | 2019-2020 | |
| Beaver-Visitec International, INC. | $197.94 | 2021 | |
| Glaukos Corporation | $169.53 | 2019 | |
| Mallinckrodt Hospital Products INC. | $135.68 | 2025 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $124.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $124.46 | 2024 | Syfovre |
| Teva Pharmaceuticals USA, INC. | $124.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $119.23 | 2024 | Quviviq |
| Kala Pharmaceuticals, INC. | $118.11 | 2021 | |
| Eyevance Pharmaceuticals LLC | $110.68 | 2019 | |
| Ani Pharmaceuticals, INC. | $102.86 | 2025 | Purified Cortrophin Gel |
| Coopervision INC. | $101.37 | 2023 | Misight Contact Lens |
| Argenx US, INC. | $74.55 | 2025 | Vyvgart Hytrulo |
| Sun Pharmaceutical Industries INC. | $22.61 | 2020 | |
| Oyster Point Pharma, INC. | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.